Mr. Carroll has been a director since June 2013 and is chair of Mallinckrodt’s Governance and Compliance Committee and a member of the company’s Portfolio Committee.
He has served as a director of TherapeuticsMD, Inc. since March 2015 and as a director of Catalent Pharma Solutions since July 2015.
Mr. Carroll served as president and chief executive officer of Boehringer Ingelheim Corporation and of Boehringer Pharmaceuticals, Inc. from 2003 until 2011 and as a director of Boehringer Ingelheim from 2003 until December 2012. He joined the organization in 2002 as president of Boehringer Pharmaceuticals, Inc. Mr. Carroll worked at Merck & Co., Inc. from 1976 to 2001. From 1972 to 1976, he served in the United States Air Force, where he attained the rank of captain. Mr. Carroll served as a director of Durata Therapeutics, Inc. from August 2014 until November 2014, when it was acquired by Actavis, as a director of VIVUS, Inc. from May 2013 until September 2014 and as a director of Inotek Pharmaceuticals Corporation from March 2016 until January 2018, including serving as chairman of Inotek from June 2016 until January 2018.
Mr. Carroll received a bachelor’s in accounting and economics from the College of the Holy Cross and an MBA from Babson College.